Table 1.
Features of patient cohorts in reference articles
| SWOG (ART vs. Observation)6 | EORTC (ART vs. Observation)3 | GCS (ART vs. Observation)7 | Stephenson (SRT)4 | |
|---|---|---|---|---|
| N | 425 | 1005 | 307 | 1603 |
| Years of study enrollment | 1988–1997 | 1992–2001 | 1997–2004 | 1987–2005 |
| Age in years, mean/median (range) | 65 (44–79) | 65 (61–69) | 65 | 62 (58–67) |
| Pre-prostatectomy PSA (ng/ml), median | 10.0 | 12.3 | 9.6 | 10.5 |
| Post-prostatectomy PSA (ng/ml) | <0.2 (66%) ≥ 0.2 (34%) | median 0.2; range (0.1–0.3) | 0 | Persistently elevated in 29%. (Pre-radiotherapy PSA = 1.1) |
| Pathologic Features | ||||
| ECE or PSM = 67% | ECE = 77% | ECE = 65%; T4 = 6% | ECE = 65% | |
| SVI = 11% | SVI = 26% | SVI = 27% | SVI = 24% | |
| ECE+ SVI + PSM = 22% | PSM = 63% | PSM = 64% | PSM = 51% | |
| Positive lymph nodes | 0% | 0.2% | 2% | 3% |
| Pathologic Grade | ||||
| ■ WHO 1 or Gleason ≤6 | 51% | 13% | 37% | 26% |
| ■ WHO 2 or Gleason 7 | 36% | 63% | 52% | 52% |
| ■ WHO 3 or Gleason 8–10 | 13% | 24% | 11% | 22% |
| Radiation Dose | 60Gy | 60Gy | 60Gy | 70Gy |
| Follow-up (mean*, median**) | 10.9* years after randomization | 5.0** years after randomization | 4.5* years after randomization | 7.5** years after prostatectomy, 4.4** years after RT |